Urologic Studies

Gerald L. Andriole, Jr., M.D.
Professor, Surgery
Chief, Division of Urologic Surgery
Director, Prostate Study Center at Barnes-Jewish Hospital, St. Louis, MO

REDUCE (REduction by DUtasteride of prostate Cancer Events)
This is a four-year industry-sponsored international study that has enrolled 8,000 men at 1000 centers across the world. The study will look at men who have suspicious PSA levels but had a negative biopsy and, therefore, have an increased risk for developing prostate cancer. The study medication is an approved drug for benign prostatic hyperplasia (dutasteride). Dr. Gerald L. Andriole is chairman of the REDUCE Steering Committee.

Complementary and Alternative Medicine for Urinary Symptoms (CAMUS)
The CAMUS study is being sponsored by National Institutes of Health (NIH)/ National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and will be approximately seven years in length. The trial will enroll approximately 3,300 subjects across the United States. Washington University will enroll 300. Phytotherapies currently are used by men for "prostate health." Although short-term trials suggest that saw palmetto and pygeum africanum reduce some lower urinary tract symptoms with few side effects, their effectiveness for preventing benign prostatic hyperplasia progression and long-term toxicity are unknown. CAMUS will compare the two phytotherapy agents to determine their effectiveness.

Other ongoing industry-sponsored studies focus on the prevention of recurrence of bladder cancer, treatment of those with high risk of renal cell cancer, treatment of metatastic and non-metatastic hormone refactory prostate cancer, and treatment of early prostate cancer (in follow-up only).

Dr. Gerald L. Andriole's CV